Peptide-based GLP-1/glucagon co-agonists: a double-edged sword to combat diabesity
If you would like to help, join the #ingredients channel on our Slack discussion space and/or learn about ingredients analysis on our wiki
Body mass index (BMI), menstrual regularity, clinical signs of hyperandrogenism, serum levels of various hormones follicular stimulating hormone (FSH), luteinizing hormone (LH) and testosterone), in addition to the clinical outcome assessed by ultrasonography, were evaluated before and after 3 months of treatment
One particularly exciting combination is GLP-1 medications with SGLT2 inhibitors
Common analytical methods include HPLC, mass spectrometry, molecular weight verification, and analytical assay testing supported by certificate of analysis documentation
Second, as a stimulant, long-term use is generally avoided to prevent potential strain on the cardiovascular system and to minimize the risk of dependency